Finoriq research workspace
Kymera Therapeutics, Inc. (KYMR) SEC Filings & Filing Highlights
Kymera Therapeutics, Inc. engages in developing KT-621, an oral STAT6 degrader in Phase 2b. Review KYMR SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
- Company
- Kymera Therapeutics, Inc. (KYMR)
- Ticker
- KYMR
- Market Cap
- $9.3B
- Latest Price
- $112.83
- Industry
- Biotech & Pharma
Kymera Therapeutics, Inc. (KYMR) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Kymera Therapeutics, Inc. (KYMR).
| Event | Form | Date |
|---|---|---|
| Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial ofKymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of | 8-K8.01 | 2026-06-25 |
| Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial ofKymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of | 8-K7.01 | 2026-06-25 |
| Proposal 1 – Election of Class III Director NomineesKymera Therapeutics, Inc. (the “Company”) held its Annual Meeting of Shareholders on June 24, 2026 (the “Annual Meeting”). At the Annual Me... | 8-K5.07 | 2026-06-24 |
| Jeremy Chadwick communicated his intention to retire and submitted his resignation as Chief Ope...Jeremy Chadwick communicated his intention to retire and submitted his resignation as Chief Operating Officer (“COO”) on June 5, 2026. Mr.... | 8-K5.02 | 2026-06-08 |
| Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Upda...Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update | 8-K2.02 | 2026-04-30 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.